Get started
Author

Qi Li

Multi-zone cooling strategy for dead-end proton exchange membrane fuel cells: Enhancing performance, water-thermal balance and durability
2026 · Zhangda Liu, Zhan Gao, et al. · Energy Conversion and Management · 4
Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
2025 · Jiayao Ni, Yi Sun, et al. · Clinical Cancer Research · 2
A glycan superbinder reveals polysialylated-CD56 as a precision biomarker for pancreatic cancer
2026 · Lingrui Huang, Song Gao, et al. · Proceedings of the National Academy of Sciences
Data from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
2026 · Jiayao Ni, Yi Sun, et al.
Supplementary Table S4 from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
2026 · Jiayao Ni, Yi Sun, et al.
Supplementary Table S2 from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
2026 · Jiayao Ni, Yi Sun, et al.
Supplementary Table S3 from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
2026 · Jiayao Ni, Yi Sun, et al.
Supplementary Table S1 from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
2026 · Jiayao Ni, Yi Sun, et al.
Supplementary Figure S1 from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
2026 · Jiayao Ni, Yi Sun, et al.
Supplementary Information1 from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
2026 · Jiayao Ni, Yi Sun, et al.
Supplementary Figure S2 from Tislelizumab and Hypofractionated Radiotherapy plus Nab-Paclitaxel/Gemcitabine as Conversion Therapy for BRPC/LAPC: A Phase II Trial with Dynamic Biomarker Monitoring
2026 · Jiayao Ni, Yi Sun, et al.
Rapid determination of diesel density using near-infrared and mid-infrared spectroscopy data fusion modelling
2026 · Chaomin Ding, Ying Kan, et al. · Fuel
Works count: 12
Citation count: 6
H-index: 2
I10-index:
Year
Topic
Type